CALGARY, June 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), announced today that Dr. Brad Thompson, President and CEO of Oncolytics, will participate in two separate presentations at the BIO 2008 International Convention.
Dr. Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June 17th at 3:30 p.m. PT at the BIO Business Forum.
On Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson is also scheduled to participate as an invited speaker as part of a panel discussion entitled "Canada: Your Global Partner for Cancer Research Innovation."
The Conference, which is expected to draw approximately 20,000 attendees, will be held at the San Diego Convention Center June 17th to June 20th, 2008.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com
The presentation times are subject to change. This release and the
presentations related thereto contain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other factors
not under the Company's control and which may cause actual results,
performance or achievements of the Company to be materially different from
the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the
efficacy of REOLYSIN(R) as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the
research and development of pha
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved